Clorox (NYSE:CLX)‘s stock had its “hold” rating reissued by stock analysts at Jefferies Group in a research note issued on Thursday. They presently have a $148.00 price objective on the stock. Jefferies Group’s price objective suggests a potential upside of 1.61% from the company’s current price.

CLX has been the topic of several other reports. Deutsche Bank assumed coverage on Clorox in a research note on Wednesday, December 13th. They set a “hold” rating and a $142.00 price objective on the stock. Royal Bank of Canada restated a “hold” rating and set a $115.00 price objective on shares of Clorox in a research note on Sunday, October 8th. Bank of America upgraded Clorox from an “underperform” rating to a “neutral” rating and set a $155.00 price objective on the stock in a research note on Thursday. BMO Capital Markets reaffirmed an “outperform” rating on shares of Clorox in a research report on Tuesday, September 12th. Finally, Wells Fargo & Co reaffirmed a “hold” rating and issued a $130.00 target price on shares of Clorox in a research report on Wednesday, December 13th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $133.33.

Shares of Clorox (NYSE CLX) traded up $2.22 on Thursday, reaching $145.65. The company had a trading volume of 585,609 shares, compared to its average volume of 950,650. Clorox has a 52-week low of $118.41 and a 52-week high of $150.40. The company has a market capitalization of $18,790.00, a PE ratio of 26.72, a PEG ratio of 3.94 and a beta of 0.42. The company has a debt-to-equity ratio of 3.02, a current ratio of 1.10 and a quick ratio of 0.77.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $1.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.41 by $0.05. Clorox had a return on equity of 161.59% and a net margin of 11.84%. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.48 billion. During the same period last year, the business posted $1.36 earnings per share. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. sell-side analysts predict that Clorox will post 5.6 EPS for the current year.

In other news, SVP Matthew T. Laszlo sold 20,051 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total transaction of $2,615,853.46. Following the transaction, the senior vice president now directly owns 10,896 shares of the company’s stock, valued at $1,421,492.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael R. Costello sold 10,574 shares of the firm’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $136.01, for a total value of $1,438,169.74. Following the transaction, the senior vice president now directly owns 34,867 shares in the company, valued at $4,742,260.67. The disclosure for this sale can be found here. 1.00% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Sun Life Financial INC grew its holdings in Clorox by 10,344.4% during the second quarter. Sun Life Financial INC now owns 940 shares of the company’s stock worth $125,000 after acquiring an additional 931 shares during the period. Acrospire Investment Management LLC acquired a new position in Clorox during the second quarter worth about $133,000. Salem Investment Counselors Inc. grew its holdings in Clorox by 2.5% during the second quarter. Salem Investment Counselors Inc. now owns 1,256 shares of the company’s stock worth $167,000 after acquiring an additional 31 shares during the period. Phocas Financial Corp. acquired a new position in Clorox during the second quarter worth about $167,000. Finally, Jacobi Capital Management LLC grew its holdings in Clorox by 0.3% during the second quarter. Jacobi Capital Management LLC now owns 1,286 shares of the company’s stock worth $172,000 after acquiring an additional 4 shares during the period. 73.14% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2018/01/04/clorox-clx-given-hold-rating-at-jefferies-group.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.